Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo

J. A. Shaw, Margaret Inkster Delday, A. W. Hart, Hilary Docherty, C. A. Maltin, Kevin Docherty

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The objective of these studies was to evaluate human insulin gene expression following intramuscular plasmid injection in non-diabetic rats as a potential approach to gene therapy for diabetes mellitus avoiding the need for immunosuppression. A wild-type human preproinsulin construct and a mutant construct in which PC2/PC3 sites were engineered to form furin consensus sites were evaluated in in vitro transfections of hepatocyte (HepG2) and myoblast (C2C12/L6) cell lines, primary rat myoblasts, and dermal fibroblasts. In vivo gene transfer by percutaneous plasmid injection of soleus muscle +/- prior notexin-induced myolysis was assessed in rats.

In vitro transfection of non-neuroendocrine cell lines and primary cultures with wild-type human preproinsulin resulted in secretion of predominantly unprocessed proinsulin. Employing the mutant construct, there was significant processing to mature insulin (HepG2, 95%; C2C12, 75%; L6, 65%; primary myoblasts, 48%; neonatal fibroblasts, 56%; adult fibroblasts, 87%). In rats aged 5 weeks, circulating human (pro)insulin was detected from 1 to 37 days following plasmid injection and the potential of augmenting transfection efficiency by prior notexin injection was demonstrated (wild-type processing, 87%; mutant, 90%). Relative hypoglycaemia was confirmed by HbA1C (saline, 5.5%; wild type, 5.1%; mutant, 5.1% (P<0.05)). Human (pro)insulin levels and processing (wild-type, 8%; mutant, 53%) were lower in rats aged 9 months but relative hypoglycaemia was confirmed by serum glucose at 10 days (saline, 6.4 mmol/l; wild-cype, 6.0 mmol/l; mutant, 5.4 mmol/l).

In conclusion, prolonged constitutive systemic secretion of bioactive human (pro)insulin has been attained in non-neuroendocrine cells in vitro and in growing and mature rats following intramuscular plasmid injection.

Original languageEnglish
Pages (from-to)653-672
Number of pages19
JournalJournal of Endocrinology
Volume172
Issue number3
DOIs
Publication statusPublished - 2002

Keywords

  • LONG-TERM EXPRESSION
  • INTRAMUSCULAR INJECTION
  • DIABETES-MELLITUS
  • MOUSE MUSCLE
  • HUMAN FIBROBLASTS
  • HUMAN PROINSULIN
  • FACTOR-IX
  • DNA
  • THERAPY
  • MICE

Cite this

Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo. / Shaw, J. A.; Delday, Margaret Inkster; Hart, A. W.; Docherty, Hilary; Maltin, C. A.; Docherty, Kevin.

In: Journal of Endocrinology, Vol. 172, No. 3, 2002, p. 653-672.

Research output: Contribution to journalArticle

@article{e73451d4e51a41aaa8422c95e8f1a946,
title = "Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo",
abstract = "The objective of these studies was to evaluate human insulin gene expression following intramuscular plasmid injection in non-diabetic rats as a potential approach to gene therapy for diabetes mellitus avoiding the need for immunosuppression. A wild-type human preproinsulin construct and a mutant construct in which PC2/PC3 sites were engineered to form furin consensus sites were evaluated in in vitro transfections of hepatocyte (HepG2) and myoblast (C2C12/L6) cell lines, primary rat myoblasts, and dermal fibroblasts. In vivo gene transfer by percutaneous plasmid injection of soleus muscle +/- prior notexin-induced myolysis was assessed in rats.In vitro transfection of non-neuroendocrine cell lines and primary cultures with wild-type human preproinsulin resulted in secretion of predominantly unprocessed proinsulin. Employing the mutant construct, there was significant processing to mature insulin (HepG2, 95{\%}; C2C12, 75{\%}; L6, 65{\%}; primary myoblasts, 48{\%}; neonatal fibroblasts, 56{\%}; adult fibroblasts, 87{\%}). In rats aged 5 weeks, circulating human (pro)insulin was detected from 1 to 37 days following plasmid injection and the potential of augmenting transfection efficiency by prior notexin injection was demonstrated (wild-type processing, 87{\%}; mutant, 90{\%}). Relative hypoglycaemia was confirmed by HbA1C (saline, 5.5{\%}; wild type, 5.1{\%}; mutant, 5.1{\%} (P<0.05)). Human (pro)insulin levels and processing (wild-type, 8{\%}; mutant, 53{\%}) were lower in rats aged 9 months but relative hypoglycaemia was confirmed by serum glucose at 10 days (saline, 6.4 mmol/l; wild-cype, 6.0 mmol/l; mutant, 5.4 mmol/l).In conclusion, prolonged constitutive systemic secretion of bioactive human (pro)insulin has been attained in non-neuroendocrine cells in vitro and in growing and mature rats following intramuscular plasmid injection.",
keywords = "LONG-TERM EXPRESSION, INTRAMUSCULAR INJECTION, DIABETES-MELLITUS, MOUSE MUSCLE, HUMAN FIBROBLASTS, HUMAN PROINSULIN, FACTOR-IX, DNA, THERAPY, MICE",
author = "Shaw, {J. A.} and Delday, {Margaret Inkster} and Hart, {A. W.} and Hilary Docherty and Maltin, {C. A.} and Kevin Docherty",
year = "2002",
doi = "10.1677/joe.0.1720653",
language = "English",
volume = "172",
pages = "653--672",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo

AU - Shaw, J. A.

AU - Delday, Margaret Inkster

AU - Hart, A. W.

AU - Docherty, Hilary

AU - Maltin, C. A.

AU - Docherty, Kevin

PY - 2002

Y1 - 2002

N2 - The objective of these studies was to evaluate human insulin gene expression following intramuscular plasmid injection in non-diabetic rats as a potential approach to gene therapy for diabetes mellitus avoiding the need for immunosuppression. A wild-type human preproinsulin construct and a mutant construct in which PC2/PC3 sites were engineered to form furin consensus sites were evaluated in in vitro transfections of hepatocyte (HepG2) and myoblast (C2C12/L6) cell lines, primary rat myoblasts, and dermal fibroblasts. In vivo gene transfer by percutaneous plasmid injection of soleus muscle +/- prior notexin-induced myolysis was assessed in rats.In vitro transfection of non-neuroendocrine cell lines and primary cultures with wild-type human preproinsulin resulted in secretion of predominantly unprocessed proinsulin. Employing the mutant construct, there was significant processing to mature insulin (HepG2, 95%; C2C12, 75%; L6, 65%; primary myoblasts, 48%; neonatal fibroblasts, 56%; adult fibroblasts, 87%). In rats aged 5 weeks, circulating human (pro)insulin was detected from 1 to 37 days following plasmid injection and the potential of augmenting transfection efficiency by prior notexin injection was demonstrated (wild-type processing, 87%; mutant, 90%). Relative hypoglycaemia was confirmed by HbA1C (saline, 5.5%; wild type, 5.1%; mutant, 5.1% (P<0.05)). Human (pro)insulin levels and processing (wild-type, 8%; mutant, 53%) were lower in rats aged 9 months but relative hypoglycaemia was confirmed by serum glucose at 10 days (saline, 6.4 mmol/l; wild-cype, 6.0 mmol/l; mutant, 5.4 mmol/l).In conclusion, prolonged constitutive systemic secretion of bioactive human (pro)insulin has been attained in non-neuroendocrine cells in vitro and in growing and mature rats following intramuscular plasmid injection.

AB - The objective of these studies was to evaluate human insulin gene expression following intramuscular plasmid injection in non-diabetic rats as a potential approach to gene therapy for diabetes mellitus avoiding the need for immunosuppression. A wild-type human preproinsulin construct and a mutant construct in which PC2/PC3 sites were engineered to form furin consensus sites were evaluated in in vitro transfections of hepatocyte (HepG2) and myoblast (C2C12/L6) cell lines, primary rat myoblasts, and dermal fibroblasts. In vivo gene transfer by percutaneous plasmid injection of soleus muscle +/- prior notexin-induced myolysis was assessed in rats.In vitro transfection of non-neuroendocrine cell lines and primary cultures with wild-type human preproinsulin resulted in secretion of predominantly unprocessed proinsulin. Employing the mutant construct, there was significant processing to mature insulin (HepG2, 95%; C2C12, 75%; L6, 65%; primary myoblasts, 48%; neonatal fibroblasts, 56%; adult fibroblasts, 87%). In rats aged 5 weeks, circulating human (pro)insulin was detected from 1 to 37 days following plasmid injection and the potential of augmenting transfection efficiency by prior notexin injection was demonstrated (wild-type processing, 87%; mutant, 90%). Relative hypoglycaemia was confirmed by HbA1C (saline, 5.5%; wild type, 5.1%; mutant, 5.1% (P<0.05)). Human (pro)insulin levels and processing (wild-type, 8%; mutant, 53%) were lower in rats aged 9 months but relative hypoglycaemia was confirmed by serum glucose at 10 days (saline, 6.4 mmol/l; wild-cype, 6.0 mmol/l; mutant, 5.4 mmol/l).In conclusion, prolonged constitutive systemic secretion of bioactive human (pro)insulin has been attained in non-neuroendocrine cells in vitro and in growing and mature rats following intramuscular plasmid injection.

KW - LONG-TERM EXPRESSION

KW - INTRAMUSCULAR INJECTION

KW - DIABETES-MELLITUS

KW - MOUSE MUSCLE

KW - HUMAN FIBROBLASTS

KW - HUMAN PROINSULIN

KW - FACTOR-IX

KW - DNA

KW - THERAPY

KW - MICE

U2 - 10.1677/joe.0.1720653

DO - 10.1677/joe.0.1720653

M3 - Article

VL - 172

SP - 653

EP - 672

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -